Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
Feature|Articles|August 6, 2026
Explicating the Status of ctDNA MRD Testing in the MIBC Treatment Paradigm
Author(s)Roman Fabbricatore
Fact checked by: Russ Conroy
Two bladder cancer specialists discussed how emerging ctDNA MRD testing advances will impact treatment selection for patients with MIBC.
Advertisement
Advertisement
The emergence of circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing, which non-invasively identifies microscopic cancer in the blood, has presented a new strategy to enhance the management of numerous cancerous malignancies.1 For bladder cancer, this testing may optimize risk stratification, inform postoperative decision-making processes, and introduce more personalized surveillance strategies for patients, particularly in treatment de-escalation.
Related to this article
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Data presented at WCLC 2026 support the use of B7-H3–directed antibody-drug conjugates and brain MRI surveillance in small cell lung cancer.
New data on antibody drug conjugates and extended survival follow-ups may inform clinical decision-making surrounding non–small cell lung cancer.
Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
Advertisement
Advertisement